January 2010 in “DOAJ (DOAJ: Directory of Open Access Journals)” IV cyclophosphamide effectively treated severe lupus nephritis in Indian patients, but longer follow-up is needed.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
4 citations
,
October 2020 in “Research Square (Research Square)” Early treatment with certain drug combinations improved COVID-19 outcomes and prevented severe disease in males, including those at higher risk.
2 citations
,
March 2013 in “BMJ Case Reports” Zinc levels remained low despite treatment, likely due to absorption issues.
2 citations
,
February 2025 in “Allergies” Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology”
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine may be effective for treating ashy dermatosis.
March 2018 in “Chin J Reprod Contracep” Chlormadinone acetate is useful for birth control and treating various hormonal issues.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
1 citations
,
February 2023 in “Plant disease” 'Eclipta prostrata' plants in Taiwan are infected with 'Candidatus Phytoplasma aurantifolia'.
July 2020 in “Indian journal of sexually transmitted diseases and AIDS” The document concludes that it's concerning when a teenage boy has both gonorrhea and syphilis at the same time.
6 citations
,
December 2022 in “Frontiers in Pharmacology” Quercetin may help improve symptoms of polycystic ovary syndrome.
49 citations
,
November 2013 in “JAMA dermatology” Clobetasol propionate, 0.05%, is more effective and safe for treating childhood alopecia areata than hydrocortisone, 1%.
Certain antiparasitics and antidepressants show promise for treating cryptococcosis, especially when combined with fluconazole.
December 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” The research suggests Dutasteride and Solifenacin may be effective against the bacterium causing listeriosis.
3 citations
,
January 2021 in “Journal of Research in Medical Sciences” Certain medications can impact metabolic syndrome, with some improving conditions like high blood sugar and others having no effect.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
5 citations
,
October 2012 in “Journal of Midwifery & Women's Health” Healthcare providers should start with simple fertility tests and treatments before referring patients to specialists.
April 2022 in “Reactions Weekly” 21 citations
,
August 2002 in “British Journal of Ophthalmology” Intralesional cidofovir may be a viable alternative treatment for SCC.
8 citations
,
July 1996 in “Annals of Internal Medicine” Itraconazole may cause low platelet and white blood cell counts.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
January 2024 in “Deleted Journal” Radiation cystitis patients need better monitoring and early treatment due to higher readmission rates.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.